-transparent.png){kind=logo}
Baseline staging bone scans in 1,267 consecutive women with breast cancer attending a single clinic between 1980 and 1986 were reviewed. 0.3% of patients with T1, 3% with T2, 8% with T3, 13% with T4 tumors and none of those with Stage 1, 3% with Stage 2, 7% with Stage 3, and 47% with Stage 4 disease had a positive scan due to bone metastases. Two hundred eight-nine (23%) had bone scan abnormalities secondary to radiologically confirmed benign bone disease. In 20 patients, no cause for a bone scan abnormality could be found after a median follow-up of 3.50 yr, a false-positive frequency of 1.6%. The false-negative rate was 0.08%. It is concluded that patients with tumors less than 2 cm are most unlikely to have a positive scan. In this instance, scans are not required routinely. However, we recommend a baseline scan in all patients with Stage 2, 3, or 4 disease.
R E Coleman, and
R D Rubens, and
I Fogelman
February 2005,
Australasian radiology,
R E Coleman, and
R D Rubens, and
I Fogelman
January 1985,
Deutsche medizinische Wochenschrift (1946),
R E Coleman, and
R D Rubens, and
I Fogelman
October 1975,
Journal of the Tennessee Medical Association,
R E Coleman, and
R D Rubens, and
I Fogelman
August 1999,
Clinical nuclear medicine,
R E Coleman, and
R D Rubens, and
I Fogelman
March 2003,
La Tunisie medicale,
R E Coleman, and
R D Rubens, and
I Fogelman
January 1997,
Tumori,
R E Coleman, and
R D Rubens, and
I Fogelman
January 2006,
The breast journal,
R E Coleman, and
R D Rubens, and
I Fogelman
March 2016,
Nuclear medicine communications,
R E Coleman, and
R D Rubens, and
I Fogelman
January 1999,
Clinical nuclear medicine,
R E Coleman, and
R D Rubens, and
I Fogelman
August 1984,
Southern medical journal,
